COMMUNIQUÉS West-GlobeNewswire

Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
28/03/2024
FDA feedback following the Company’s submission of a Pre-IND briefing package improves clarity on regulatory requirements for Phase 2b influenza A clinical trial with oral CC-42344, a broad-spectrum PB2 inhibitor [...]
4DMT Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis
28/03/2024
Conducted initial pivotal study interactions with the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA); Company has clear registration path for 4D-710 for treatment of cystic fibrosis (CF) [...]
Larkspur Biosciences to Present New Preclinical Research on Lead Development Program Candidate, a First-in-Class PIP4K2C Protein Degrader, at AACR 2024
28/03/2024
LRK-A drives monotherapy anti-tumor activity, including complete tumor regressions, in CRC patient samples and an in vivo model IND-enabling studies are under way; Larkspur is moving rapidly toward clinical development [...]
QHSLab Announces Impressive 2023 Fiscal Year Results with Growing Revenues, Improved Gross Margins, and Substantial Reduction in Net Loss
28/03/2024
WEST PALM BEACH, FL, March 28, 2024 (GLOBE NEWSWIRE) -- QHSLab, Inc. (the “Company”) (OTCQB: USAQ), a company focused on providing clinicians with tools to leverage proactive, value-based healthcare solutions through [...]
IMUNON Reports 2023 Financial Results and Provides Business Update
28/03/2024
Conference Call Begins Today at 10:00 a.m. Eastern Time LAWRENCEVILLE, N.J., March 28, 2024 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN) , a clinical-stage drug-development company focused on developing DNA-mediated [...]
Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the SIRS 2024 Annual Meeting
28/03/2024
CUPERTINO, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet [...]
BrainsWay Announces Positive Results in Late-Life Depression Post-Marketing Analysis
28/03/2024
Data Published in Leading Peer-Reviewed Publication, Journal of Clinical Medicine JERUSALEM and BURLINGTON, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company [...]
Arcutis to Present at the 23rd Annual Needham Virtual Healthcare Conference
28/03/2024
WESTLAKE VILLAGE, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology [...]
Affimed Reports 2023 Financial Results and Operational Progress
28/03/2024
AFM24 combination with atezolizumab (AFM24-102): Follow-up of the Phase 1/2a combination study confirmed four responses in the non-small cell cancer (NSCLC) EGFR -wildtype cohort: one complete response (CR), three [...]
Teleflex’s Climate Targets Validated by the Science Based Targets Initiative
28/03/2024
Teleflex commits to reach net-zero greenhouse gas emissions across its value chain by 2050. WAYNE, Pa., March 28, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical [...]
Zymeworks Announces Appointment of Dr. Neil Gallagher to its Board of Directors
28/03/2024
VANCOUVER, British Columbia, March 28, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve [...]
Photomedicine Pioneer CLINUVEL Unveils Clinical, Cosmetic Ambitions to German Investors
28/03/2024
DÜSSELDORF, Germany, March 28, 2024 (GLOBE NEWSWIRE) -- Pioneering biopharmaceutical company CLINUVEL yesterday hosted a wide-ranging market briefing discussing its novel drug SCENESSE ® (afamelanotide) and the future [...]
Inventiva announces the nomination of Andre Turenne as Director
28/03/2024
Daix (France), Long Island City (New York, United States), March 28, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small [...]
Inventiva annonce la nomination d’Andre Turenne en tant qu’administrateur
28/03/2024
Daix (France), Long Island City (New York, États-Unis), le 28 mars 2024 – Inventiva (Euronext Paris et Nasdaq : IVA) (la "Société"), société biopharmaceutique spécialisée dans le développement clinique de petites [...]
Intravacc and Primrose Bio Announce Partnership to Enhance Conjugate Vaccine Development
28/03/2024
The companies will leverage their combined experience in the development of conjugate vaccines for their clients Primrose Bio will supply its industry-leading carrier protein, PeliCRM197 ® , for vaccine development [...]
Sequana Medical announces 2023 Full Year Results and 2024 Outlook
28/03/2024
PRESS RELEASE REGULATED INFORMATION – INSIDE INFORMATION 28 March 2024, 08:00 a.m. CET alfapump ® – PMA 1 submitted to US FDA and accepted for substantive review, extensive feedback just received from FDA which is [...]
Medigene AG Reports Full-Year 2023 Financial Results and Provides Corporate Update
28/03/2024
Significant corporate and scientific progress in 2023 Innovations to End-to-End Platform technologies and IP portfolio Pipeline additions with multiple KRAS neoantigen targets Advancement of lead program MDG1015 with [...]
2023 Universal Registration Document
28/03/2024
Press Release Paris – March 28, 2024 – EUROAPI today announces that its 2023 Universal Registration Document will be filed with the French Financial Markets Authority (AMF) on April 5, 2024. Financial calendar May 22, [...]
Document d’Enregistrement Universel 2023
28/03/2024
Communiqué de presse Paris – Le 28 mars 2024 – EUROAPI annonce aujourd’hui que son Document d’Enregistrement Universel 2023 sera déposé auprès de l’Autorité des Marchés Financiers (AMF) le 5 avril 2024. Calendrier [...]

Pages